Afterwards, a prospective multicenter evaluation of CD133 immunostaining on a larger population of surgically resected colon cancers is warranted to allow a conclusive and definitive assessment of its suitability in predicting tumor aggressiveness and outcome in colon cancer patients. Here, PROM1 is linked to malignant colon neoplasm.